GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK (GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. Read more here.

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy areas including cancer, diabetes and – inevitably – obesity. Four of ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

The European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent ...

We are proud Jemperli continues to redefine the treatment landscape for patients," said Hesham Abdullah, GSK's global head of Oncology. Endometrial cancer, the most common gynecologic cancer in ...